Parenteral Estrogen May Reduce Hormone Agonist Toxicity in Advanced Prostate Cancer

First, I must apologize for having ignored the blog over the last two weeks. I have been intensely focused on the launch of a new project that we at Malecare have been developing. It has managed to take up every available second of my time. At this moment, I am not able to describe much [...]

Understanding & Using Estrogen as Hormone Therapy (ADT)

An alternative to standard hormone therapy (ADT) using luteinizing hormone-releasing hormone (LHRH) analogs like leuprolide (Lupron®, Eligard®), goserelin (Zoladex®), triptorelin (Trelstar®), and histrelin (Vantas®) for men with advanced prostate cancer, but often not used is estradiol (a form of estrogen). When estrogens were first used as a therapy for men with advanced prostate cancer they [...]

Some Side Effects of Androgen Deprivation Therapy (ADT) Induced by Estrogen Deficiency

Androgen deprivation therapy (ADT) is an old standby for the treatment of men with metastatic or advanced prostate cancer. We have long known that testosterone plays an integral role in the progression of prostate cancer, thus we often use it as an initial treatment for men who become metastatic. ADT is used both for men [...]

Estrogen May Play Role in Melanoma Recurrence- A Warning for Those of Us Who Are Considering Estrogen as a Second Line ADT

According to a an article published in the January 2012 issue of Cancer Prevention Research, estrogen may play a role in Melanoma recurrences! The article described a large cohort study of women who were put on an anti-estrogen therapy. The study concluded that those women on the anti-estrogen therapy had a lower risk of melanoma. [...]

Capesaris™ (GTx-758) Phase II Proof of Concept Trial – A New On the Horizon Drug To Watch

GTx, Inc. this weekend presented results of the Capesaris™ (GTx-758) proof of concept pharmacokinetic-pharmacodynamic (PK/PD) clinical trial treating men with advanced prostate cancer, at the Annual Meeting of the Society of Urologic Oncology. Capesaris is a novel oral selective estrogen receptor alpha agonist which GTx is developing for first line treatment of advanced prostate cancer. [...]

Estrogen – A Second Line Hormone Therapy (Part 2 of a Series of Posts on Second Line Hormone Therapy)

One of the earliest hormone therapies (ADT) given to men to treat prostate cancer was estrogen. Estrogen, commonly known as the female hormone, was used as an ADT treatment in the early 1950s. […]

Estrogen, An Alternative Hormone Deprivation Drug

The occasionally discussed, but not often used, alternative hormone therapy, transdermal estrogen might be ready to soon move on to a phase III trial. A poster presentation of a phase II trial showed that transdermal estrogen patches drove down testosterone and PSA levels to a similar extent as an LHRH analog. The poster presentation was [...]

Estrogen May Play Negative Role In Prostate Cancer

CAUTION, some doctors use estrogen patches as a form of first line hormone blockade therapy for the treatment of prostate cancer. However, scientists from Weill Cornell Medical College, New York City have described the hormone estrogen as a potential key negative player in about half of all prostate cancers. Researchers have found that Estrogen-linked signaling [...]

Go to Top